De-implementing inhaled corticosteroids to improve quality and safety for patients with mild-to-moderate COPD: Mixed-methods findings of primary-care providers’ perspectives
Christian Helfrich, PhD, MPH
Krysttel Stryczek, MA
Seminar date: 12/7/2017
Description: Inhaled corticosteroids (ICS) are widely used to treat mild to moderate chronic obstructive pulmonary disease (COPD) despite an increased risk of pneumonia and the availability of safer alternatives. As part of a quality improvement initiative to discontinue inappropriate ICS therapy, we used interviews and surveys to explore primary care providers’ experiences prescribing ICS for patients with mild to moderate COPD. In this Cyberseminar we will discuss findings about the role of multiple prescribing providers and awareness of practice guidelines, and implications for other efforts to de-prescribe ineffective or harmful therapies.
Intended audience: Researchers studying de-implementation of ineffective and harmful practices and clinicians and administrators interested in patient safety.